Adynxx Inc ADYX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.60
- Market Cap
- $5.81
- Volume/Avg
- 601 / 362
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- http://www.adynxx.com
Valuation
|
Metric
|
ADYX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADYX
|
|---|---|
Quick Ratio | 0.02 |
Current Ratio | 0.18 |
Interest Coverage | −2.61 |
Quick Ratio
ADYX
Profitability
|
Metric
|
ADYX
|
|---|---|
Return on Assets (Normalized) | −129.94% |
Return on Equity (Normalized) | −1,026.61% |
Return on Invested Capital (Normalized) | −148.29% |
Return on Assets
ADYX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jhrwffxxk | Wqrr | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bldmhyp | Xypmwr | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fwlgwfml | Bnlbf | $99.6 Bil | |
MRNA
| Moderna Inc | Lsftvscm | Bqxd | $38.8 Bil | |
ARGX
| argenx SE ADR | Lqxmpmsr | Pfpl | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Fhqnklk | Mydq | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xsdbjwx | Hzfflf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sqpfvyvw | Skphfl | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dkbnlbkx | Xwlyz | $12.4 Bil | |
INCY
| Incyte Corp | Fxmpfdr | Kwwbfd | $11.9 Bil |